个人中心 - 老虎社区

paul96

IP属地：未知

帖子 · 196帖子 · 196
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- paul96paul96
  ·2021-12-16
  Like ols
  非常抱歉，此主贴已删除
  1,741 3
  6
  分享
  举报
- paul96paul96
  ·2021-12-13
  Hehehs
  Rivian,Adobe,FedEx,Lennar,Campbell Soup,and Other Stocks to Watch This Week
  The main event for investors this week will be the Federal Reserve’s rate-setting committee’s last meeting of 2021. Recent commentary from officials has leaned more hawkish, setting up a potential announcement of plans to accelerate monthly asset purchase tapering.The Federal Open Market Committee’s two-day meeting takes place on Tuesday and Wednesday.Earnings reports this week are few, but will include Campbell Soup on Tuesday;Lennar,Accenture,FedEx,Rivian Automotive, and Adobe on Thursday; and
  Rivian,Adobe,FedEx,Lennar,Campbell Soup,and Other Stocks to Watch This Week
  1,911 2
  3
  分享
  举报
- paul96paul96
  ·2021-11-21
  Like pla
  非常抱歉，此主贴已删除
  1,685 1
  4
  分享
  举报
- paul96paul96
  ·2021-11-19
  Like
  Toplines Before US Market Open on Friday
  Nasdaq index futures hit a record high on Friday as investors sought economically stable sectors aft
  Toplines Before US Market Open on Friday
  1,691 评论
  7
  分享
  举报
- paul96paul96
  ·2021-11-17
  Like pls
  非常抱歉，此主贴已删除
  1,741 1
  2
  分享
  举报
- paul96paul96
  ·2021-11-16
  Like pls
  非常抱歉，此主贴已删除
  1,826 1
  4
  分享
  举报
- paul96paul96
  ·2021-11-15
  Like pls
  非常抱歉，此主贴已删除
  1,820 2
  5
  分享
  举报
- paul96paul96
  ·2021-11-13
  Like pls
  Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.
  Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo
  Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.
  1,276 1
  7
  分享
  举报
- paul96paul96
  ·2021-11-10
  Like pls
  非常抱歉，此主贴已删除
  1,266 评论
  2
  分享
  举报
- paul96paul96
  ·2021-11-07
  Like pls
  非常抱歉，此主贴已删除
  1,653 1
  6
  分享
  举报
暂无粉丝

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3566471223304091","uuid":"3566471223304091","gmtCreate":1603379163363,"gmtModify":1614327560642,"name":"paul96","pinyin":"paul96","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/532ca1e4472c5ea6253974f44276245f","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":13,"headSize":469,"tweetSize":196,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.56%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.07","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.30%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":690098539,"gmtCreate":1639611837025,"gmtModify":1639611837193,"author":{"id":"3566471223304091","authorId":"3566471223304091","name":"paul96","avatar":"https://static.tigerbbs.com/532ca1e4472c5ea6253974f44276245f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566471223304091","authorIdStr":"3566471223304091"},"themes":[],"htmlText":"Like ols","listText":"Like ols","text":"Like ols","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/690098539","repostId":"2191994940","repostType":4,"isVote":1,"tweetType":1,"viewCount":1741,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604346785,"gmtCreate":1639354941783,"gmtModify":1639354941946,"author":{"id":"3566471223304091","authorId":"3566471223304091","name":"paul96","avatar":"https://static.tigerbbs.com/532ca1e4472c5ea6253974f44276245f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566471223304091","authorIdStr":"3566471223304091"},"themes":[],"htmlText":"Hehehs","listText":"Hehehs","text":"Hehehs","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/604346785","repostId":"1171271872","repostType":4,"repost":{"id":"1171271872","kind":"news","pubTimestamp":1639348466,"share":"https://www.laohu8.com/m/news/1171271872?lang=&edition=full","pubTime":"2021-12-13 06:34","market":"us","language":"en","title":"Rivian,Adobe,FedEx,Lennar,Campbell Soup,and Other Stocks to Watch This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=1171271872","media":"Barrons","summary":"The main event for investors this week will be the Federal Reserve’s rate-setting committee’s last meeting of 2021. Recent commentary from officials has leaned more hawkish, setting up a potential announcement of plans to accelerate monthly asset purchase tapering.The Federal Open Market Committee’s two-day meeting takes place on Tuesday and Wednesday.Earnings reports this week are few, but will include Campbell Soup on Tuesday;Lennar,Accenture,FedEx,Rivian Automotive, and Adobe on Thursday; and","content":"<p>The main event for investors this week will be the Federal Reserve’s rate-setting committee’s&nbsp;last meeting of 2021. Recent commentary from officials has leaned more hawkish, setting up a potential announcement of plans to accelerate monthly asset purchase tapering.</p>\n<p>The Federal Open Market Committee’s two-day meeting takes place on Tuesday and Wednesday.</p>\n<p>Earnings reports this week are few, but will include&nbsp;Campbell Soup&nbsp;on Tuesday;Lennar,Accenture,FedEx,Rivian&nbsp;Automotive, and&nbsp;Adobe&nbsp;on Thursday; and&nbsp;Darden Restaurants&nbsp;on Friday.</p>\n<p>Economic data coming out this week includes the Bureau of Labor Statistics’ producer price index for November on Tuesday. Economists expect a 0.55% month-over-month rise for the headline index and a 0.4% gain for the core PPI. Those would both roughly match October’s pace of producer inflation.</p>\n<p>Other data releases include the National Federation of Independent Businesses’ sentiment&nbsp;index on Tuesday, November retail-sales spending from the Census Bureau on Wednesday, and the November housing starts on Thursday.</p>\n<p><b>Monday 12/13</b></p>\n<p>J.Jill&nbsp;and&nbsp;PHX Minerals&nbsp;host earnings conference calls.</p>\n<p><b>Tuesday 12/14</b></p>\n<p>Campbell Soup, Barnes Group, and&nbsp;Avaya Holdings&nbsp;host investor days.</p>\n<p><b>The Bureau of Labor</b>&nbsp;Statistics releases the producer price index for November. Consensus estimate is for a 0.55% month-over-month rise, and for the core PPI, which excludes food and energy, to gain 0.4%. This compares with increases of 0.6% and 0.4%, respectively, in October.</p>\n<p><b>The National Federation</b>&nbsp;of Independent Businesses reports its index, which surveys about 5,000 small-business owners across the country, for November. Expectations call for a reading of 98.3, compared with 98.2 in October.</p>\n<p><b>Wednesday 12/15</b></p>\n<p><b>The Federal Open Market Committee</b> concludes its two-day meeting, when policy makers will discuss accelerating the timetable for tapering monthly securities purchases.</p>\n<p><b>The BLS reports</b> export and import price data for November. Expectations are for a 0.5% month-over-month rise in export prices, while import prices are seen increasing 0.5%. This compares with gains of 1.5% and 1.2%, respectively, in October.</p>\n<p><b>The National Association</b> of Home Builders releases its NAHB/Wells Fargo Housing Market Index for December. Consensus estimate is for an 84 reading, compared with an 83 reading in November. The index peaked at 90 late last year, and home builders remain bullish on the housing market.</p>\n<p><b>The Census Bureau</b> reports on retail-sales spending for November. Expectations are for a seasonally adjusted 0.7% month-over-month increase in retail sales, compared with a 1.7% rise in October. Excluding autos, spending is seen rising 0.8%, compared with 1.7% in the previous period.</p>\n<p><b>Thursday 12/16</b></p>\n<p>Heico,Lennar, Accenture, FedEx, Jabil, Adobe, Rivian Automotive, and Nordson are among companies hosting earnings conference calls.</p>\n<p><b>The Census Bureau</b>releases its New Residential Construction report for November. The seasonally adjusted annual rate of housing starts is expected to be 1.563 million units, compared with 1.52 million in October. A housing start is counted when excavation begins on a home. Permits issued for new-home construction are expected to be 1.655 million, compared with 1.653 million in October.</p>\n<p><b>The Bank of England</b> announces its interest-rate decision and publishes the minutes of the meeting.</p>\n<p><b>The Federal Reserve</b> releases industrial production data for November. Economists are looking for a 0.6% rise, after a 1.6% increase in October. Capacity utilization is expected at 76.8, roughly in line with October’s 76.4%.</p>\n<p><b>Friday 12/17</b></p>\n<p>Steelcase,Darden Restaurants, and&nbsp;Quanex Building Products&nbsp;host earnings conference calls.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rivian,Adobe,FedEx,Lennar,Campbell Soup,and Other Stocks to Watch This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRivian,Adobe,FedEx,Lennar,Campbell Soup,and Other Stocks to Watch This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-13 06:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/stocks-to-watch-this-week-fedex-rivian-lennar-campbell-adobe-51639330550?mod=hp_LEAD_3><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The main event for investors this week will be the Federal Reserve’s rate-setting committee’s last meeting of 2021. Recent commentary from officials has leaned more hawkish, setting up a potential ...</p>\n\n<a href=\"https://www.barrons.com/articles/stocks-to-watch-this-week-fedex-rivian-lennar-campbell-adobe-51639330550?mod=hp_LEAD_3\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DRI":"达登饭店","LEN":"莱纳建筑公司",".IXIC":"NASDAQ Composite","PHX":"潘汉德尔油气","HEI":"海科航空","JILL":"J.Jill Inc.","SCS":"Steelcase Inc.","FDX":"联邦快递","RIVN":"Rivian Automotive, Inc.","ADBE":"Adobe","ACN":"埃森哲",".SPX":"S&P 500 Index",".DJI":"道琼斯","CPB":"金宝汤"},"source_url":"https://www.barrons.com/articles/stocks-to-watch-this-week-fedex-rivian-lennar-campbell-adobe-51639330550?mod=hp_LEAD_3","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171271872","content_text":"The main event for investors this week will be the Federal Reserve’s rate-setting committee’s last meeting of 2021. Recent commentary from officials has leaned more hawkish, setting up a potential announcement of plans to accelerate monthly asset purchase tapering.\nThe Federal Open Market Committee’s two-day meeting takes place on Tuesday and Wednesday.\nEarnings reports this week are few, but will include Campbell Soup on Tuesday;Lennar,Accenture,FedEx,Rivian Automotive, and Adobe on Thursday; and Darden Restaurants on Friday.\nEconomic data coming out this week includes the Bureau of Labor Statistics’ producer price index for November on Tuesday. Economists expect a 0.55% month-over-month rise for the headline index and a 0.4% gain for the core PPI. Those would both roughly match October’s pace of producer inflation.\nOther data releases include the National Federation of Independent Businesses’ sentiment index on Tuesday, November retail-sales spending from the Census Bureau on Wednesday, and the November housing starts on Thursday.\nMonday 12/13\nJ.Jill and PHX Minerals host earnings conference calls.\nTuesday 12/14\nCampbell Soup, Barnes Group, and Avaya Holdings host investor days.\nThe Bureau of Labor Statistics releases the producer price index for November. Consensus estimate is for a 0.55% month-over-month rise, and for the core PPI, which excludes food and energy, to gain 0.4%. This compares with increases of 0.6% and 0.4%, respectively, in October.\nThe National Federation of Independent Businesses reports its index, which surveys about 5,000 small-business owners across the country, for November. Expectations call for a reading of 98.3, compared with 98.2 in October.\nWednesday 12/15\nThe Federal Open Market Committee concludes its two-day meeting, when policy makers will discuss accelerating the timetable for tapering monthly securities purchases.\nThe BLS reports export and import price data for November. Expectations are for a 0.5% month-over-month rise in export prices, while import prices are seen increasing 0.5%. This compares with gains of 1.5% and 1.2%, respectively, in October.\nThe National Association of Home Builders releases its NAHB/Wells Fargo Housing Market Index for December. Consensus estimate is for an 84 reading, compared with an 83 reading in November. The index peaked at 90 late last year, and home builders remain bullish on the housing market.\nThe Census Bureau reports on retail-sales spending for November. Expectations are for a seasonally adjusted 0.7% month-over-month increase in retail sales, compared with a 1.7% rise in October. Excluding autos, spending is seen rising 0.8%, compared with 1.7% in the previous period.\nThursday 12/16\nHeico,Lennar, Accenture, FedEx, Jabil, Adobe, Rivian Automotive, and Nordson are among companies hosting earnings conference calls.\nThe Census Bureaureleases its New Residential Construction report for November. The seasonally adjusted annual rate of housing starts is expected to be 1.563 million units, compared with 1.52 million in October. A housing start is counted when excavation begins on a home. Permits issued for new-home construction are expected to be 1.655 million, compared with 1.653 million in October.\nThe Bank of England announces its interest-rate decision and publishes the minutes of the meeting.\nThe Federal Reserve releases industrial production data for November. Economists are looking for a 0.6% rise, after a 1.6% increase in October. Capacity utilization is expected at 76.8, roughly in line with October’s 76.4%.\nFriday 12/17\nSteelcase,Darden Restaurants, and Quanex Building Products host earnings conference calls.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9,"ACN":0.9,"ADBE":0.9,"AVYA":0.9,"CPB":0.9,"DRI":0.9,"FDX":0.9,"HEI":0.9,"JILL":0.9,"LEN":0.9,"PHX":0.9,"RIVN":0.9,"SCS":0.9}},"isVote":1,"tweetType":1,"viewCount":1911,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872190952,"gmtCreate":1637454712922,"gmtModify":1637460629756,"author":{"id":"3566471223304091","authorId":"3566471223304091","name":"paul96","avatar":"https://static.tigerbbs.com/532ca1e4472c5ea6253974f44276245f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566471223304091","authorIdStr":"3566471223304091"},"themes":[],"htmlText":"Like pla","listText":"Like pla","text":"Like pla","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/872190952","repostId":"2184384295","repostType":4,"isVote":1,"tweetType":1,"viewCount":1685,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876594728,"gmtCreate":1637329661826,"gmtModify":1637329662107,"author":{"id":"3566471223304091","authorId":"3566471223304091","name":"paul96","avatar":"https://static.tigerbbs.com/532ca1e4472c5ea6253974f44276245f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566471223304091","authorIdStr":"3566471223304091"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876594728","repostId":"1156692377","repostType":4,"repost":{"id":"1156692377","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637326873,"share":"https://www.laohu8.com/m/news/1156692377?lang=&edition=full","pubTime":"2021-11-19 21:01","market":"us","language":"en","title":"Toplines Before US Market Open on Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=1156692377","media":"Tiger Newspress","summary":"Nasdaq index futures hit a record high on Friday as investors sought economically stable sectors aft","content":"<p>Nasdaq index futures hit a record high on Friday as investors sought economically stable sectors after a small delay in voting on President Joe Biden's $1.75 trillion spending bill, while rising COVID-19 cases in Europe also dented sentiment.</p>\n<p>S&amp;P and Dow futures fell tracking losses in banks, airlines, and other economically sensitive sectors. Uncertainty over rising inflation and the Federal Reserve's tightening also kept demand for value stocks low.</p>\n<p>At 7:55 a.m. ET, Dow e-minis were down 250 points, or 0.7%. S&amp;P 500 e-minis were down 14 points, or 0.3% and Nasdaq 100 e-minis were up 66.25 points, or 0.4%.</p>\n<p><img src=\"https://static.tigerbbs.com/4d60c72fda7c9c4bcde12af36bdc2f99\" tg-width=\"414\" tg-height=\"185\" referrerpolicy=\"no-referrer\"></p>\n<p>Shares of Alphabet Inc, Amazon.com&nbsp;and Microsoft Corp&nbsp;- stocks which have largely persevered through economic shocks since 2020, rose between 0.3% and 0.6% in premarket trade.</p>\n<p>Chipmaker Nvidia&nbsp;also boosted Nasdaq futures, rising 1.4% in heavy trade after posting strong quarterly results late Wednesday.</p>\n<p>On the other hand, carriers Delta Air Lines, United Airlines&nbsp;and American Airlines, and cruiseliners Norwegian Cruise Line&nbsp;and Carnival Corp&nbsp;fell between 1.4% and 3%.</p>\n<p>Oil firms Exxon Mobil&nbsp;and Chevron Corp&nbsp;slipped 2.7% and 2.4% as crude prices sank, while big banks including JPMorgan Chase &amp; Co&nbsp;and Bank of America&nbsp;were down between 1.6% and 1.9%, tracking a fall in U.S. Treasury yields.</p>\n<p><b>Stocks making the biggest moves premarket:</b></p>\n<p><b>Moderna(</b><b>MRNA</b><b>)</b>&nbsp;–&nbsp;Moderna stock surged 5% in premarket trading&nbsp;after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.</p>\n<p><b>Farfetch(FTCH)</b> – The online luxury fashion marketplace operator’s shares plunged 22.1% in the premarket after it reported a narrower-than-expected quarterly loss and saw revenue fall short of Wall Street forecasts. The company also gave weaker-than-expected adjusted earnings guidance.</p>\n<p><b>Applied Materials(AMAT)</b> – Applied Materials came in a penny shy of estimates with adjusted quarterly earnings of $1.94 per share. The semiconductor equipment maker’s revenue fell short of forecasts as well. Applied Materials also gave a weaker-than-expected current-quarter outlook amid supply shortages of certain components, and its stock tumbled 6.2% in premarket action.</p>\n<p><b>Foot Locker(FL)</b> – Foot Locker slid 7.1% in the premarket after the athletic footwear and apparel retailer said it expects global supply chain constraints to persist through this quarter. The slide comes despite a beat on both the top and bottom lines for Foot Locker’s most recent quarter, as well as better-than-expected comparable store sales.</p>\n<p><b>Intuit(INTU)</b> – Intuit earned an adjusted $1.53 per share for its latest quarter, well above analyst forecasts for a profit of 97 cents per share. The financial software firm also reported better-than-expected revenue and gave an upbeat forecast as it benefits from its acquisition of Credit Karma late last year and MailChimp last month. Its stock surged 13% in premarket trading.</p>\n<p><b>Ross Stores(ROST)</b> – Ross Stores reported quarterly earnings of $1.09 per share, topping the 78-cent consensus estimate, with revenue also beating forecasts. However, the discount retailer said it was seeing significant supply chain issues, causing uncertainty heading into the holiday shopping season, and the stock slid 3.4% in the premarket.</p>\n<p><b>SoFi(SOFI)</b> – SoFi fell 1.8% in premarket action following news that investor Chamath Palihapitiya sold 15% of his stake in the fintech firm to help build his cash reserves and fund new investments.</p>\n<p><b>Workday(WDAY)</b> – Workday beat estimates by 24 cents with adjusted quarterly earnings of $1.10 per share, while the maker of human resources software saw revenue top estimates amid faster growth in subscription revenue. However, the company said the effects of the Covid-19 pandemic will weigh on growth in the coming year, and the stock tumbled 7.5% in premarket trading.</p>\n<p><b>Buckle(BKE)</b> – The fashion accessories retailer’s stock rallied 10.7% in the premarket following an upbeat quarterly earnings report. The company earned $1.26 per share for the quarter, beating the 92-cent consensus estimate, with revenue also topping Street projections.</p>\n<p><b>Dillard’s(DDS)</b> – The department store operator’s stock added 3.2% in premarket trading after the company announced a $15 per share special dividend, payable on December 15 to shareholders of record as of November 29.</p>\n<p><b>Williams-Sonoma(WSM)</b> – Williams-Sonoma reported adjusted quarterly earnings of $3.32 per share, beating the consensus estimate of $3.14. The housewares retailer saw better-than-expected revenue and raised its full-year forecast, noting a strong jump in e-commerce and strength across its brands. Williams-Sonoma also reported higher-than-expected selling, general and administrative expenses during the quarter, and the stock fell 7.1% in the premarket after rising in five of the past six sessions.</p>\n<p><b>Palo Alto Networks(PANW)</b> – Palo Alto shares jumped 4.3% in premarket trading, reversing initial losses that occurred after the cybersecurity firm gave weaker-than-expected full-year guidance. Palo Alto beat forecasts on the top and bottom lines for its most recent quarter, earning an adjusted $1.64 per share compared with a consensus estimate of $1.57.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Friday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Friday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-19 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Nasdaq index futures hit a record high on Friday as investors sought economically stable sectors after a small delay in voting on President Joe Biden's $1.75 trillion spending bill, while rising COVID-19 cases in Europe also dented sentiment.</p>\n<p>S&amp;P and Dow futures fell tracking losses in banks, airlines, and other economically sensitive sectors. Uncertainty over rising inflation and the Federal Reserve's tightening also kept demand for value stocks low.</p>\n<p>At 7:55 a.m. ET, Dow e-minis were down 250 points, or 0.7%. S&amp;P 500 e-minis were down 14 points, or 0.3% and Nasdaq 100 e-minis were up 66.25 points, or 0.4%.</p>\n<p><img src=\"https://static.tigerbbs.com/4d60c72fda7c9c4bcde12af36bdc2f99\" tg-width=\"414\" tg-height=\"185\" referrerpolicy=\"no-referrer\"></p>\n<p>Shares of Alphabet Inc, Amazon.com&nbsp;and Microsoft Corp&nbsp;- stocks which have largely persevered through economic shocks since 2020, rose between 0.3% and 0.6% in premarket trade.</p>\n<p>Chipmaker Nvidia&nbsp;also boosted Nasdaq futures, rising 1.4% in heavy trade after posting strong quarterly results late Wednesday.</p>\n<p>On the other hand, carriers Delta Air Lines, United Airlines&nbsp;and American Airlines, and cruiseliners Norwegian Cruise Line&nbsp;and Carnival Corp&nbsp;fell between 1.4% and 3%.</p>\n<p>Oil firms Exxon Mobil&nbsp;and Chevron Corp&nbsp;slipped 2.7% and 2.4% as crude prices sank, while big banks including JPMorgan Chase &amp; Co&nbsp;and Bank of America&nbsp;were down between 1.6% and 1.9%, tracking a fall in U.S. Treasury yields.</p>\n<p><b>Stocks making the biggest moves premarket:</b></p>\n<p><b>Moderna(</b><b>MRNA</b><b>)</b>&nbsp;–&nbsp;Moderna stock surged 5% in premarket trading&nbsp;after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.</p>\n<p><b>Farfetch(FTCH)</b> – The online luxury fashion marketplace operator’s shares plunged 22.1% in the premarket after it reported a narrower-than-expected quarterly loss and saw revenue fall short of Wall Street forecasts. The company also gave weaker-than-expected adjusted earnings guidance.</p>\n<p><b>Applied Materials(AMAT)</b> – Applied Materials came in a penny shy of estimates with adjusted quarterly earnings of $1.94 per share. The semiconductor equipment maker’s revenue fell short of forecasts as well. Applied Materials also gave a weaker-than-expected current-quarter outlook amid supply shortages of certain components, and its stock tumbled 6.2% in premarket action.</p>\n<p><b>Foot Locker(FL)</b> – Foot Locker slid 7.1% in the premarket after the athletic footwear and apparel retailer said it expects global supply chain constraints to persist through this quarter. The slide comes despite a beat on both the top and bottom lines for Foot Locker’s most recent quarter, as well as better-than-expected comparable store sales.</p>\n<p><b>Intuit(INTU)</b> – Intuit earned an adjusted $1.53 per share for its latest quarter, well above analyst forecasts for a profit of 97 cents per share. The financial software firm also reported better-than-expected revenue and gave an upbeat forecast as it benefits from its acquisition of Credit Karma late last year and MailChimp last month. Its stock surged 13% in premarket trading.</p>\n<p><b>Ross Stores(ROST)</b> – Ross Stores reported quarterly earnings of $1.09 per share, topping the 78-cent consensus estimate, with revenue also beating forecasts. However, the discount retailer said it was seeing significant supply chain issues, causing uncertainty heading into the holiday shopping season, and the stock slid 3.4% in the premarket.</p>\n<p><b>SoFi(SOFI)</b> – SoFi fell 1.8% in premarket action following news that investor Chamath Palihapitiya sold 15% of his stake in the fintech firm to help build his cash reserves and fund new investments.</p>\n<p><b>Workday(WDAY)</b> – Workday beat estimates by 24 cents with adjusted quarterly earnings of $1.10 per share, while the maker of human resources software saw revenue top estimates amid faster growth in subscription revenue. However, the company said the effects of the Covid-19 pandemic will weigh on growth in the coming year, and the stock tumbled 7.5% in premarket trading.</p>\n<p><b>Buckle(BKE)</b> – The fashion accessories retailer’s stock rallied 10.7% in the premarket following an upbeat quarterly earnings report. The company earned $1.26 per share for the quarter, beating the 92-cent consensus estimate, with revenue also topping Street projections.</p>\n<p><b>Dillard’s(DDS)</b> – The department store operator’s stock added 3.2% in premarket trading after the company announced a $15 per share special dividend, payable on December 15 to shareholders of record as of November 29.</p>\n<p><b>Williams-Sonoma(WSM)</b> – Williams-Sonoma reported adjusted quarterly earnings of $3.32 per share, beating the consensus estimate of $3.14. The housewares retailer saw better-than-expected revenue and raised its full-year forecast, noting a strong jump in e-commerce and strength across its brands. Williams-Sonoma also reported higher-than-expected selling, general and administrative expenses during the quarter, and the stock fell 7.1% in the premarket after rising in five of the past six sessions.</p>\n<p><b>Palo Alto Networks(PANW)</b> – Palo Alto shares jumped 4.3% in premarket trading, reversing initial losses that occurred after the cybersecurity firm gave weaker-than-expected full-year guidance. Palo Alto beat forecasts on the top and bottom lines for its most recent quarter, earning an adjusted $1.64 per share compared with a consensus estimate of $1.57.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INTU":"财捷",".IXIC":"NASDAQ Composite","ROST":"罗斯百货有限公司","MRNA":"Moderna, Inc.","DDS":"狄乐百货",".SPX":"S&P 500 Index",".DJI":"道琼斯","WSM":"Williams-Sonoma Inc","AMAT":"应用材料","SOFI":"SoFi Technologies Inc.","BKE":"巴克尔"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156692377","content_text":"Nasdaq index futures hit a record high on Friday as investors sought economically stable sectors after a small delay in voting on President Joe Biden's $1.75 trillion spending bill, while rising COVID-19 cases in Europe also dented sentiment.\nS&P and Dow futures fell tracking losses in banks, airlines, and other economically sensitive sectors. Uncertainty over rising inflation and the Federal Reserve's tightening also kept demand for value stocks low.\nAt 7:55 a.m. ET, Dow e-minis were down 250 points, or 0.7%. S&P 500 e-minis were down 14 points, or 0.3% and Nasdaq 100 e-minis were up 66.25 points, or 0.4%.\n\nShares of Alphabet Inc, Amazon.com and Microsoft Corp - stocks which have largely persevered through economic shocks since 2020, rose between 0.3% and 0.6% in premarket trade.\nChipmaker Nvidia also boosted Nasdaq futures, rising 1.4% in heavy trade after posting strong quarterly results late Wednesday.\nOn the other hand, carriers Delta Air Lines, United Airlines and American Airlines, and cruiseliners Norwegian Cruise Line and Carnival Corp fell between 1.4% and 3%.\nOil firms Exxon Mobil and Chevron Corp slipped 2.7% and 2.4% as crude prices sank, while big banks including JPMorgan Chase & Co and Bank of America were down between 1.6% and 1.9%, tracking a fall in U.S. Treasury yields.\nStocks making the biggest moves premarket:\nModerna(MRNA) – Moderna stock surged 5% in premarket trading after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.\nFarfetch(FTCH) – The online luxury fashion marketplace operator’s shares plunged 22.1% in the premarket after it reported a narrower-than-expected quarterly loss and saw revenue fall short of Wall Street forecasts. The company also gave weaker-than-expected adjusted earnings guidance.\nApplied Materials(AMAT) – Applied Materials came in a penny shy of estimates with adjusted quarterly earnings of $1.94 per share. The semiconductor equipment maker’s revenue fell short of forecasts as well. Applied Materials also gave a weaker-than-expected current-quarter outlook amid supply shortages of certain components, and its stock tumbled 6.2% in premarket action.\nFoot Locker(FL) – Foot Locker slid 7.1% in the premarket after the athletic footwear and apparel retailer said it expects global supply chain constraints to persist through this quarter. The slide comes despite a beat on both the top and bottom lines for Foot Locker’s most recent quarter, as well as better-than-expected comparable store sales.\nIntuit(INTU) – Intuit earned an adjusted $1.53 per share for its latest quarter, well above analyst forecasts for a profit of 97 cents per share. The financial software firm also reported better-than-expected revenue and gave an upbeat forecast as it benefits from its acquisition of Credit Karma late last year and MailChimp last month. Its stock surged 13% in premarket trading.\nRoss Stores(ROST) – Ross Stores reported quarterly earnings of $1.09 per share, topping the 78-cent consensus estimate, with revenue also beating forecasts. However, the discount retailer said it was seeing significant supply chain issues, causing uncertainty heading into the holiday shopping season, and the stock slid 3.4% in the premarket.\nSoFi(SOFI) – SoFi fell 1.8% in premarket action following news that investor Chamath Palihapitiya sold 15% of his stake in the fintech firm to help build his cash reserves and fund new investments.\nWorkday(WDAY) – Workday beat estimates by 24 cents with adjusted quarterly earnings of $1.10 per share, while the maker of human resources software saw revenue top estimates amid faster growth in subscription revenue. However, the company said the effects of the Covid-19 pandemic will weigh on growth in the coming year, and the stock tumbled 7.5% in premarket trading.\nBuckle(BKE) – The fashion accessories retailer’s stock rallied 10.7% in the premarket following an upbeat quarterly earnings report. The company earned $1.26 per share for the quarter, beating the 92-cent consensus estimate, with revenue also topping Street projections.\nDillard’s(DDS) – The department store operator’s stock added 3.2% in premarket trading after the company announced a $15 per share special dividend, payable on December 15 to shareholders of record as of November 29.\nWilliams-Sonoma(WSM) – Williams-Sonoma reported adjusted quarterly earnings of $3.32 per share, beating the consensus estimate of $3.14. The housewares retailer saw better-than-expected revenue and raised its full-year forecast, noting a strong jump in e-commerce and strength across its brands. Williams-Sonoma also reported higher-than-expected selling, general and administrative expenses during the quarter, and the stock fell 7.1% in the premarket after rising in five of the past six sessions.\nPalo Alto Networks(PANW) – Palo Alto shares jumped 4.3% in premarket trading, reversing initial losses that occurred after the cybersecurity firm gave weaker-than-expected full-year guidance. Palo Alto beat forecasts on the top and bottom lines for its most recent quarter, earning an adjusted $1.64 per share compared with a consensus estimate of $1.57.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9,"AMAT":0.9,"BKE":0.9,"DDS":0.9,"FL":0.9,"FTCH":0.9,"ESmain":0.9,"NQmain":0.9,"YMmain":0.9,"INTU":0.9,"MRNA":0.9,"ROST":0.9,"SOFI":0.9,"WSM":0.9}},"isVote":1,"tweetType":1,"viewCount":1691,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871409484,"gmtCreate":1637102792623,"gmtModify":1637102796931,"author":{"id":"3566471223304091","authorId":"3566471223304091","name":"paul96","avatar":"https://static.tigerbbs.com/532ca1e4472c5ea6253974f44276245f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566471223304091","authorIdStr":"3566471223304091"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/871409484","repostId":"1112207087","repostType":4,"isVote":1,"tweetType":1,"viewCount":1741,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871976757,"gmtCreate":1637022913244,"gmtModify":1637022913339,"author":{"id":"3566471223304091","authorId":"3566471223304091","name":"paul96","avatar":"https://static.tigerbbs.com/532ca1e4472c5ea6253974f44276245f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566471223304091","authorIdStr":"3566471223304091"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/871976757","repostId":"2183282074","repostType":4,"isVote":1,"tweetType":1,"viewCount":1826,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873203044,"gmtCreate":1636943067612,"gmtModify":1636943067744,"author":{"id":"3566471223304091","authorId":"3566471223304091","name":"paul96","avatar":"https://static.tigerbbs.com/532ca1e4472c5ea6253974f44276245f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566471223304091","authorIdStr":"3566471223304091"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/873203044","repostId":"2183536049","repostType":4,"isVote":1,"tweetType":1,"viewCount":1820,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873084702,"gmtCreate":1636800448611,"gmtModify":1636800448734,"author":{"id":"3566471223304091","authorId":"3566471223304091","name":"paul96","avatar":"https://static.tigerbbs.com/532ca1e4472c5ea6253974f44276245f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566471223304091","authorIdStr":"3566471223304091"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/873084702","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","kind":"news","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p>\n<p>“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p>\n<p>Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p>\n<p>Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p>\n<p>In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p>\n<p>The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p>\n<p>Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p>\n<p>The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p>\n<p>The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p>\n<p>The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p>\n<p>While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p>\n<p>In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p>\n<p>The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p>\n<p>“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p>\n<p>Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p>\n<p>“[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p>\n<p>The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p>\n<p>“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p>\n<p>Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p>\n<p>“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p>\n<p>Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p>\n<p>“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p>\n<p>That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p>\n<p>Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p>\n<p>Moderna shares are down more than 40% over the past three months.</p>\n<p>As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p>\n<p>When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p>\n<p>That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p>\n<p>Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p>\n<p>Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p>\n<p>An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-13 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that...</p>\n\n<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1276,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":847886877,"gmtCreate":1636506551697,"gmtModify":1636506583593,"author":{"id":"3566471223304091","authorId":"3566471223304091","name":"paul96","avatar":"https://static.tigerbbs.com/532ca1e4472c5ea6253974f44276245f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566471223304091","authorIdStr":"3566471223304091"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/847886877","repostId":"1188205095","repostType":4,"isVote":1,"tweetType":1,"viewCount":1266,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":842770762,"gmtCreate":1636249067342,"gmtModify":1636249516541,"author":{"id":"3566471223304091","authorId":"3566471223304091","name":"paul96","avatar":"https://static.tigerbbs.com/532ca1e4472c5ea6253974f44276245f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3566471223304091","authorIdStr":"3566471223304091"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/842770762","repostId":"2181074782","repostType":4,"isVote":1,"tweetType":1,"viewCount":1653,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"followers","isTTM":false}